Business
Result of AGM
Result of AGM.
About this update from Verici Dx Plc
[{"type":"text","content":"\n\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\") \n \nResult of AGM and voting results\n \nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the Annual General Meeting (\"AGM\") held earlier today, all resolutions were duly passed.\n \nThe voting results of the AGM were as follows:\n \n\n\n\n\n\n\n\nIn Favour\n\n\nAgainst\n\n\nWithheld\n\n\n\n\nResolution\n\n\nVotes\n\n\n%\n\n\nVotes\n\n\n%\n\n\nVotes\n\n\n\n\n1\n\n\n109,919,167\n\n\n97.96\n\n\n2,287,678\n\n\n2.04\n\n\n76\n\n\n\n\n2\n\n\n112,096,318\n\n\n99.90\n\n\n110,603\n\n\n0.10\n\n\n0\n\n\n\n\n3\n\n\n112,205,310\n\n\n99.99\n\n\n1,611\n\n\n0.01\n\n\n0\n\n\n\n\n4\n\n\n112,081,736\n\n\n99.89\n\n\n125,185\n\n\n0.11\n\n\n0\n\n\n\n\n5\n\n\n112,085,956\n\n\n99.89\n\n\n120,965\n\n\n0.11\n\n\n0\n\n\n\n\n6\n\n\n111,792,090\n\n\n99.63\n\n\n414,740\n\n\n0.37\n\n\n91\n\n\n\n\n7\n\n\n112,203,528\n\n\n99.99\n\n\n3,233\n\n\n0.01\n\n\n160\n\n\n\n\n8\n\n\n112,192,472\n\n\n99.99\n\n\n14,289\n\n\n0.01\n\n\n160\n\n\n\n\n9\n\n\n112,154,800\n\n\n99.95\n\n\n51,921\n\n\n0.05\n\n\n200\n\n\n\n\n \n \nEnquiries:\n \n\n\n\n\nVerici Dx\n\n\nwww.vericidx.com\n\n\n\n\nSara Barrington, CEO \n\n\[email protected]\n\n\n\n\nJulian Baines, Chairman\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\n\n\nTel: +44 20 7496 3000\n\n\n\n\nAubrey Powell / Sam Butcher\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \nAbout Verici Dx plc www.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science ...